Prostate Cancer - Results from #19120

#GU15 - Prostate Cancer Keynote: Can epigenetic alterations in human cancers be exploited for cancer screening, detection, diagnosis and treatment? - Session Highlights February 27, 2015

Prevalence of prostatic calcification subtypes and association with prostate cancer - Abstract February 27, 2015

#GU15 - Prostate cancer: Year in review - Session Highlights February 27, 2015

#GU15 - ASCENDE-RT: A multicenter, randomized trial of dose-escalated external beam radiation therapy (EBRT-B) versus low-dose-rate brachytherapy (LDR-B) for men with unfavorable-risk localized prostate cancer - Session Highlights February 27, 2015

Multiparametric MRI-targeted TRUS prostate biopsies using visual registration - Abstract February 27, 2015

Night shift work, chronotype and prostate cancer risk in the MCC-Spain case-control study - Abstract February 27, 2015

Minimally important difference for the expanded Prostate Cancer Index Composite Short Form - Abstract February 27, 2015

#GU15 - ADT plus docetaxel versus ADT alone for hormone-naïve metastatic prostate cancer: Long-term analysis of the GETUG-AFU 15 phase III trial - Session Highlights February 27, 2015

Impact of prostate-specific antigen on a baseline prostate cancer risk assessment including genetic risk - Abstract February 27, 2015

#GU15 - Characterization of abiraterone responses in African American men with castrate resistant prostate cancer - Session Highlights February 27, 2015

The role of dietary fat throughout the prostate cancer trajectory - Abstract February 27, 2015

Bladder wall recurrence of prostate cancer after high-dose-rate brachytherapy - Abstract February 26, 2015

A national multicenter phase 2 study of prostate-specific antigen (PSA) pox virus vaccine with sequential androgen ablation therapy in patients with PSA progression: ECOG 980 - Abstract February 26, 2015

#GU15 - Poster: Response to taxane chemotherapy as first subsequent therapy after abiraterone acetate (AA) in patients with metastatic castration-resistant prostate cancer (mCRPC): Post-hoc analysis of COU-AA-302 February 26, 2015

#GU15 - Response to taxane chemotherapy as first subsequent therapy after abiraterone acetate (AA) in patients with metastatic castration-resistant prostate cancer (mCRPC): Post-hoc analysis of COU-AA-302 - Session Highlights February 26, 2015

#GU15 - Quantitative total bone imaging (QTBI) in patients with metastatic castration-resistant prostate cancer (CRPC) using NaF PET/CT - Session Highlights February 26, 2015

#GU15 - AR-based biomarker association with response to abiraterone in mCRPC - Session Highlights February 26, 2015

#GU15 - Antigen-specific immune responses through 24 months in the STAND trial: A randomized phase 2 study evaluating optimal sequencing of sipuleucel-T and androgen deprivation therapy in biochemically-recurrent prostate cancer - Session Highlights February 26, 2015

#GU15 - Assessment of corticosteroid-associated adverse events with long-term exposure to low-dose prednisone given with abiraterone acetate in mCRPC - Session Highlights February 26, 2015

Risk of cardiovascular events with degarelix versus leuprolide after biochemical relapse of prostate cancer: Exploratory analysis of a randomized controlled trial - Session Highlights February 26, 2015

Page 957 of 1457